The tweet was deleted by the author.
But we saved everything 🙂.
OmniAb has entered into a Technology License and Services Agreement with a newly-formed incubated company of ArrowMark Partners and Viking Global Investors.
This strategic partnership is aimed at enhancing antibody discovery processes leveraging innovative technologies. OmniAb, known for cutting-edge solutions in the immunology space, seeks to expand its footprint through this collaboration, aligning with prominent investment firms. ArrowMark and Viking Global continue to diversify their portfolios by backing ventures at the forefront of biotech research. This move underscores a growing trend of investment in the biotechnology sector, fostering advancements in therapeutic development.